Coherus BioSciences, Inc.’s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues
The Coherus BioSciences, Inc. (NASDAQ:CHRS) share price has fared very poorly over the last month, falling by a substantial 32%. For any long-term shareholders, the last month ends a year to forget by locking in a 64% share price decline.
Since its price has dipped substantially, Coherus BioSciences may look like a strong buying opportunity at present with its price-to-sales (or “P/S”) ratio of 0.3x, considering almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 8x and even P/S higher than 45x aren’t out of the ordinary. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.
Our free stock report includes 6…
